Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
Open Access
- 10 March 2015
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 278 (1), 1-18
- https://doi.org/10.1111/joim.12360
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide and is a growing health problem that is associated with a significantly increased risk of stroke and thromboembolism. Oral anticoagulant (OAC) therapy reduces the risk of stroke and all‐cause mortality in patients with AF. OAC therapy is commonly given as a well‐controlled vitamin K antagonist (VKA; e.g. warfarin) and can reduce the risk of stroke in AF patients by almost two‐thirds. However, the widespread use of VKAs has been hampered by the unpredictable pharmacokinetic and pharmacodynamic properties of the drugs and justifiable concerns about the consequent risk of haemorrhage. The non‐VKA OACs (NOACs) have revolutionized thromboprophylaxis in AF by providing therapeutic options with predictable pharmacodynamic and pharmacokinetic properties that are as efficacious as warfarin in the prevention of stroke and thromboembolism but are more convenient to use. In this review, we provide a patient‐centred framework to assist clinicians in recommending the right OAC therapy to fit the individual patient with AF, including methods for stratifying the risk of stroke and haemorrhage and the chances of achieving tight control of VKA anticoagulation, and we discuss the properties of the NOACs that favour their use in particular patient cohorts.Keywords
Funding Information
- Daiichi Sankyo Europe GmbH
This publication has 101 references indexed in Scilit:
- Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH RegistryEuropean Journal of Preventive Cardiology, 2013
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysisBMC Family Practice, 2012
- Direct thrombin inhibitorsBritish Journal of Clinical Pharmacology, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) StudyJournal of the American College of Cardiology, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortalityEP Europace, 2010
- Translating the Results of Randomized Trials into Clinical PracticeStroke, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006